For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development expenses | 9,981 | |||
| Selling, general and administrative expenses | 10,918 | |||
| Loss from operations | -20,899 | |||
| Realized gain from sales of trading securities | 1,126 | |||
| Unrealized loss from trading securities | -391 | |||
| Interest income | 692 | |||
| Total other income | 1,427 | |||
| Net loss | -19,472 | |||
| Basic EPS | -33.06 | |||
| Diluted EPS | -33.06 | |||
| Basic Average Shares | 589,000 | |||
| Diluted Average Shares | 589,000 | |||
enVVeno Medical Corp (NVNO)
enVVeno Medical Corp (NVNO)